An Interview with Ron Bartek, Founding President of the Freidriech's Ataxia Research Alliance (FARA)

Larry Luxner, senior corespondent for Rare Disease Advisor, interviews Ron Bartek, founding president of the Freidriech's Ataxia Research Alliance (FARA), about the hope generated by the recent FDA approval of Reata's omaveloxolone (Skyclarys)—the first-ever therapy to treat this rare neuromuscular disease.